Clinical Trial Update: RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab

View source ↗

Summary

This clinical trial update discusses a study evaluating a RAS switch strategy in patients with metastatic colorectal cancer treated with first-line FOLFIRI plus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)

Snippet

Sponsor: Sofia Perea, Director Clinical Trials Unit. | Conditions: Colorectal Cancer Metastatic | Status: UNKNOWN